A Deep-Dive into Efruxifermin as a therapy for nonalcoholic steatohepatitisTicker(s): AKRO
Institution: Arizona Liver Health (ALH)
- The VP of Academic Affairs, Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health (ALH) in Phoenix, AZ.
- Treats 1000 patients with NASH.
- Fellowship trained (Adult Transplant Hepatology) at the Cleveland Clinic.
- Specializes in nonalcoholic fatty liver disease, viral hepatitis, autoimmune hepatitis, alpha 1 antitrypsin deficiency, and liver transplantation; has over 160 publications and presents his work at both national and international medical conferences.
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.